Nurix Therapeutics (NRIX) Depreciation & Amortization (CF) (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $2.2 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $2.2 million, down 6.55% year-over-year; the trailing twelve-month figure through Feb 2026 was $8.6 million (down 10.61% YoY), and the FY2025 annual result was $8.7 million, down 6.02% from the prior year.
• Depreciation & Amortization (CF) advanced to $2.2 million in Q1 2026 per NRIX's latest filing, from $2.1 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $2.5 million in Q4 2024 and troughed at $991000.0 in Q1 2022.
• A 5-year average of $1.9 million and a median of $2.0 million in 2025 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 116.67% in 2022, then decreased 16.24% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.6 million in 2022, then increased by 17.42% to $1.9 million in 2023, then surged by 33.14% to $2.5 million in 2024, then slipped by 16.24% to $2.1 million in 2025, then gained by 3.58% to $2.2 million in 2026.
• Business Quant data shows NRIX's Depreciation & Amortization (CF) at $2.2 million in Q1 2026, $2.1 million in Q4 2025, and $2.0 million in Q3 2025.